MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

REGN · NASDAQ-GS

Regeneron Pharmaceuticals, Inc.

Health Care · Biotechnology: Pharmaceutical Preparations

Reference price$695.18As of Jul 28, 2026
Market capitalization$72.88B
52-week range$541.00–$821.11
S&P 500 portfolio weight0.10%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$641.00-7.8% vs. reference
Average$814.90+17.2% vs. reference
High$1,000.00+43.8% vs. reference
15 Buy6 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportJul 30, 2026Jun 2026
Consensus EPS$8.006 estimates
Expected range$5.66–$10.21Low to high EPS
Dec 2026$37.12Street EPS consensus
Dec 2027$42.26Street EPS consensus
Dec 2028$46.72Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+1.0% YoY$14.34B$14.2B
Operating income$3.58B$3.99B
Net income$4.5B$4.41B
Operating cash flow$4.98B$4.42B
Capital expenditures($0.9B)($0.76B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?

Zacks

Will REGN's Q2 Earnings Get a Boost From Dupixent and Eylea HD?

Zacks

Curious about Regeneron (REGN) Q2 Performance? Explore Wall Street Estimates for Key Metrics

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.